Brentuximab vedotin (BV) is a compound of CD30 mAb linked to cytotoxic moiety monomethyl auristatin (MMAE) and directed against CD30, which disrupts the microtubules resulting in apoptosis of targeting tumor cells (Fig. 2). Here, TNFRSF8 is linked to neoplasm.